Mostrar el registro sencillo del ítem

dc.contributor.authorTamayo Angorrilla, Marta
dc.contributor.authorLópez de Andrés, Julia 
dc.contributor.authorJiménez González, Gema 
dc.contributor.authorMarchal Corrales, Juan Antonio 
dc.date.accessioned2023-03-07T11:49:49Z
dc.date.available2023-03-07T11:49:49Z
dc.date.issued2021-11-27
dc.identifier.citationMarta Tamayo-Angorrilla... [et al.]. The biomimetic extracellular matrix: a therapeutic tool for breast cancer research, Translational Research, Volume 247, 2022, Pages 117-136, ISSN 1931-5244, [https://doi.org/10.1016/j.trsl.2021.11.008]es_ES
dc.identifier.urihttps://hdl.handle.net/10481/80452
dc.description.abstractBackground: A deeper knowledge of the functional versatility and dynamic nature of the ECM has improved the understanding of cancer biology. Translational Significance: This work provides an in-depth view of the importance of the ECM to develop more mimetic breast cancer models, which aim to recreate the components and architecture of tumor microenvironment. Special focus is placed on decellularized matrices derived from tissue and cell culture, both in procurement and applications, as they have achieved great success in cancer research and pharmaceutical sector. The extracellular matrix (ECM) is increasingly recognized as a master regulator of cell behavior and response to breast cancer (BC) treatment. During BC progression, the mammary gland ECM is remodeled and altered in the composition and organization. Accumulated evidence suggests that changes in the composition and mechanics of ECM, orchestrated by tumor-stromal interactions along with ECM remodeling enzymes, are actively involved in BC progression and metastasis. Understanding how specific ECM components modulate the tumorigenic process has led to an increased interest in the development of biomaterial-based biomimetic ECM models to recapitulate key tumor characteristics. The decellularized ECMs (dECMs) have emerged as a promising in vitro 3D tumor model, whose recent advances in the processing and application could become the biomaterial by excellence for BC research and the pharmaceutical industry. This review offers a detailed view of the contribution of ECM in BC progression, and highlights the application of dECM-based biomaterials as promising personalized tumor models that more accurately mimic the tumorigenic mechanisms of BC and the response to treatment. This will allow the design of targeted therapeutic approaches adapted to the specific characteristics of each tumor that will have a great impact on the precision medicine applied to BC patients. (Translational Research 2022; 247:117 136)es_ES
dc.description.sponsorshipJunta de Andalucia PIN-0224-2019es_ES
dc.description.sponsorshipConvocatoria de Proyectos Intramurales ibs.GRANADA INTRAIBS-2020-10es_ES
dc.description.sponsorshipSpanish Government RTI2018-101309-B-C22es_ES
dc.description.sponsorshipJunta de Andalucia P18-FR-2470 SOMM17/6109/UGRes_ES
dc.description.sponsorshipMinistry of Economy and Competitiveness, Instituto de Salud Carlos III PIE16/00045 DTS19/00143 DTS17/00087es_ES
dc.description.sponsorshipChair "Doctors GaleraRequena in cancer stem cell research" CMC-CTS963 Universidad de Granada/CBUAes_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleThe Biomimetic Extracellular Matrix: a Therapeutic Tool for Breast Cancer Researches_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1016/j.trsl.2021.11.008
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional